Home LiteratureArticle Details
PMID: 1692080 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors.

The Journal of experimental medicine ·Vol. 171 ·No. 5 ·1990-05-01 ·Pages 1509-26

Caligiuri MA, Zmuidzinas A, Manley TJ, Levine H, Smith KA, Ritz J

Abstract

In this study, we have used radiolabeled IL-2 binding assays, Northern blot analysis, immunofluorescent flow cytometry and cell sorting, as well as proliferation and cytotoxicity assays to perform an extensive phenotypic and functional characterization of the IL-2 receptor in normal resting human peripheral blood lymphocytes. Our results indicate that almost all T cells (greater than 98%) express neither the high affinity IL-2 receptor nor the functional intermediate affinity p75 chain of the IL-2 receptor without prior activation. In contrast, most NK cells constitutively express the isolated intermediate affinity p75 IL-2 receptor. In addition, a subpopulation of NK cells, distinguished by high density expression of the NKH1 antigen, constitutively express the high affinity IL-2 receptor, in addition to an excess of the isolated intermediate affinity p75 IL-2 receptor. These NKH1bright+ cells exhibit a brisk proliferative response to IL-2, similar to that seen with antigen-activated T cells, yet do so in the absence of any known antigenic stimuli. No other resting peripheral blood lymphocyte population, including CD4+, CD8+, and CD20 cells, exhibits this property. The intermediate affinity p75 IL-2 receptor, as it exists in its isolated form on resting NK cells, does not transduce a growth signal equivalent to that seen in NK cells expressing the high affinity IL-2 receptor, despite doses of IL-2 that are known to fully saturate the isolated p75 chain. This strongly suggests that additional structural or functional components are involved in generating the proliferative response following the binding of IL-2 to the high affinity heterodimeric form of the IL-2 receptor. The constitutive expression of this functional high affinity IL-2 receptor on a small population of resting NK cells provides further evidence in support of a role for these cells in the host's early defense against viral infection or malignant transformation, before the more delayed but specific T cell response.

MeSH Terms
Antibodies, Monoclonal Antigens, CD/analysis Blotting, Northern Fluorescent Antibody Technique Humans Interleukin-2/metabolism Killer Cells, Natural/cytology,immunology Lymphocyte Activation Lymphocytes/cytology,immunology Nucleic Acid Hybridization RNA/genetics,isolation & purification Receptors, Interleukin-2/biosynthesis,genetics,immunology
Chemicals
Antibodies, Monoclonal Antigens, CD Interleukin-2 Receptors, Interleukin-2 RNA
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Caligiuri M A
Division of Tumor Immunology, Dana-Farber Cancer Institute, Boston, MA 02115.
Zmuidzinas A
Manley T J
Levine H
Smith K A
Ritz J
References (48)
48 references, click to expand
  1. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    J Immunol. 1986 May 15;136(10):3899-909 PMID: 2871106
  2. Human T lymphocyte subsets. Functional heterogeneity and surface recognition structures.
    J Clin Invest. 1984 Nov;74(5):1559-65 PMID: 6389597
  3. Novel interleukin 2 (IL-2) receptor appears to mediate IL-2-induced activation of natural killer cells.
    J Clin Invest. 1988 Jan;81(1):200-5 PMID: 2826541
  4. Direct activation of human resting T cells by IL 2: the role of an IL 2 receptor distinct from the Tac protein.
    J Immunol. 1987 Sep 1;139(5):1550-6 PMID: 3040856
  5. Recombinant interleukin-2-induced polyclonal proliferation of in vitro unstimulated human peripheral blood lymphocytes.
    Cell Immunol. 1986 Apr 1;98(2):396-410 PMID: 3019569
  6. Interleukin 2 (IL 2) up-regulates its own receptor on a subset of human unprimed peripheral blood lymphocytes and triggers their proliferation.
    J Immunol. 1986 Apr 1;136(7):2463-9 PMID: 3005412
  7. Adoptive transfer studies demonstrating the antiviral effect of natural killer cells in vivo.
    J Exp Med. 1985 Jan 1;161(1):40-52 PMID: 2981954
  8. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes.
    J Immunol. 1986 Jun 15;136(12):4480-6 PMID: 3086432
  9. Proliferation of human peripheral blood lymphocytes induced by recombinant human interleukin 2: contribution of large granular lymphocytes and T lymphocytes.
    Cell Immunol. 1986 Oct 15;102(2):261-72 PMID: 3100057
  10. Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex.
    Proc Natl Acad Sci U S A. 1986 Dec;83(24):9694-8 PMID: 3099289
  11. Interleukin 2 high-affinity receptor expression requires two distinct binding proteins.
    J Exp Med. 1987 Jan 1;165(1):223-38 PMID: 3098894
  12. The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells.
    Proc Natl Acad Sci U S A. 1987 Aug;84(15):5394-8 PMID: 3110786
  13. The interleukin 2 receptor. Functional consequences of its bimolecular structure.
    J Exp Med. 1987 Oct 1;166(4):1055-69 PMID: 3116143
  14. A second human interleukin-2 binding protein that may be a component of high-affinity interleukin-2 receptors.
    Nature. 1987 Jun 11-17;327(6122):518-22 PMID: 3108674
  15. In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy.
    J Clin Oncol. 1987 Dec;5(12):1933-41 PMID: 3500280
  16. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.
    N Engl J Med. 1987 Apr 9;316(15):889-97 PMID: 3493432
  17. Induction of proliferation in vitro of resting human natural killer cells: IL 2 induces into cell cycle most peripheral blood NK cells, but only a minor subset of low density T cells.
    J Immunol. 1986 Dec 15;137(12):3845-54 PMID: 3491151
  18. Recombinant interleukin 2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens.
    J Immunol. 1985 Feb;134(2):794-801 PMID: 3871216
  19. Regulation of cellular function by products of lysosomal enzyme activity: elimination of human natural killer cells by a dipeptide methyl ester generated from L-leucine methyl ester by monocytes or polymorphonuclear leukocytes.
    Proc Natl Acad Sci U S A. 1985 Apr;82(8):2468-72 PMID: 3857595
  20. Effects of natural and recombinant IL 2 on regulation of IFN gamma production and natural killer activity: lack of involvement of the Tac antigen for these immunoregulatory effects.
    J Immunol. 1984 Aug;133(2):779-83 PMID: 6203980
  21. Interleukin-2 augments natural killer cell activity.
    Nature. 1981 May 28;291(5813):335-8 PMID: 6164929
  22. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity.
    Anal Biochem. 1983 Jul 1;132(1):6-13 PMID: 6312838
  23. Triggering of the T3-Ti antigen-receptor complex results in clonal T-cell proliferation through an interleukin 2-dependent autocrine pathway.
    Proc Natl Acad Sci U S A. 1984 Mar;81(5):1509-13 PMID: 6231642
  24. Transient expression of interleukin 2 receptors. Consequences for T cell growth.
    J Exp Med. 1983 Dec 1;158(6):1895-911 PMID: 6606011
  25. Interleukin 2 dependence of human natural killer (NK) cell activity.
    J Immunol. 1983 Apr;130(4):1970-3 PMID: 6601144
  26. Increase in NK cell number and turnover rate during acute viral infection.
    J Immunol. 1983 Sep;131(3):1539-45 PMID: 6886424
  27. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells.
    J Immunol. 1981 Apr;126(4):1393-7 PMID: 6970774
  28. Blastogenesis of natural killer cells during viral infection in vivo.
    J Immunol. 1982 Dec;129(6):2788-95 PMID: 7142707
  29. Cytotoxic cells induced during lymphocytic choriomeningitis virus infection of mice. I. Characterization of natural killer cell induction.
    J Exp Med. 1978 Jul 1;148(1):163-81 PMID: 307587
  30. Functional heterogeneity of Leu 19"bright"+ and Leu 19"dim"+ lymphokine-activated killer cells.
    J Immunol. 1989 Apr 15;142(8):2949-54 PMID: 2467946
  31. Regulation of virus infections by natural killer cells. A review.
    Nat Immun Cell Growth Regul. 1986;5(4):169-99 PMID: 2430177
  32. Analysis of T-cell receptor gene rearrangement and expression in human natural killer clones.
    Science. 1985 Jun 28;228(4707):1540-3 PMID: 2409597
  33. Activation of human thymocytes via the 50KD T11 sheep erythrocyte binding protein induces the expression of interleukin 2 receptors on both T3+ and T3- populations.
    J Immunol. 1985 Jan;134(1):330-5 PMID: 2578045
  34. Activation of peripheral blood T cells via the p75 interleukin 2 receptor.
    J Exp Med. 1989 Oct 1;170(4):1445-50 PMID: 2571670
  35. Severe herpesvirus infections in an adolescent without natural killer cells.
    N Engl J Med. 1989 Jun 29;320(26):1731-5 PMID: 2543925
  36. CD3-negative natural killer cells express zeta TCR as part of a novel molecular complex.
    Nature. 1989 Sep 14;341(6238):159-62 PMID: 2528695
  37. The interleukin 2 receptor.
    Annu Rev Cell Biol. 1989;5:397-425 PMID: 2688708
  38. Monoclonal antibody defining a molecule possibly identical to the p75 subunit of interleukin 2 receptor.
    J Exp Med. 1989 Apr 1;169(4):1323-32 PMID: 2784485
  39. Activation of natural killer cells via the p75 interleukin 2 receptor.
    J Exp Med. 1989 Jul 1;170(1):291-6 PMID: 2787381
  40. IL-2 receptors on circulating natural killer cells and T lymphocytes. Similarity in number and affinity but difference in transmission of the proliferation signal.
    J Immunol. 1989 Jan 15;142(2):490-9 PMID: 2783438
  41. Interleukin-2 receptor beta chain gene: generation of three receptor forms by cloned human alpha and beta chain cDNA's.
    Science. 1989 May 5;244(4904):551-6 PMID: 2785715
  42. Natural killer cells: a primitive immune system.
    Nature. 1989 Sep 14;341(6238):108 PMID: 2779647
  43. Appearance and phenotypic characterization of circulating Leu 19+ cells in cancer patients receiving recombinant interleukin 2.
    Cancer Res. 1988 Nov 15;48(22):6597-602 PMID: 2902918
  44. Cloning, sequence and expression of human interleukin-2 receptor.
    Nature. 1984 Dec 20-1985 Jan 2;312(5996):768-71 PMID: 6096720
  45. Molecular cloning of cDNA encoding human interleukin-2 receptor.
    Nature. 1984 Oct 18-24;311(5987):631-5 PMID: 6090949
  46. Molecular cloning and expression of cDNAs for the human interleukin-2 receptor.
    Nature. 1984 Oct 18-24;311(5987):626-31 PMID: 6090948
  47. Response of resting human peripheral blood natural killer cells to interleukin 2.
    J Exp Med. 1984 Oct 1;160(4):1147-69 PMID: 6434688
  48. Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome.
    J Immunol. 1987 Nov 15;139(10):3306-13 PMID: 2824604
Article Info
Journal
The Journal of experimental medicine
Abbr.
J Exp Med
ISSN
0022-1007
Published
1990-05-01
Pages
1509-26
Language
English
Region
United States
NLM ID
2985109R
PMCID
PMC2187895
Subset
IM
Grants
NCI NIH HHS · CA-17643 · United States
NCI NIH HHS · CA-41619 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]